The i31-SLNB Identifies Patients With Cutaneous Melanoma Who Have Less Than 5% Risk of SLN Positivity While the CP-GEP Does Not. J of Skin 2025, 9 (2), s563. https://doi.org/10.25251/skin.10.supp.563.